Shingles Vaccine Market By Product (Shingrix, and Zostavax), Patient Type (Pediatric Patients & Adult Patients) and Region (North America, Europe, Asia Pacific, and the Rest of the World (RoW)) - Global Analysis & Forecast 2019-2030

Report ID : 125  |  Published Date : Nov 2019  |  Pages : 150  |  Region : Global  |  Report Code : PH-8





Shingles Vaccine Market Overview and Introduction

Shingles Vaccine Market is estimated to be valued at ~US$ 1,999.5 million in 2019.  It is anticipated to further grow at a CAGR of ~7.4% from 2019 to 2030. 

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. Vaccination is one of the most effective ways to prevent diseases. A vaccine helps the body’s immune system to recognize and fight pathogens like viruses or bacteria, which then keeps us safe from the diseases they cause. Vaccines are made using the disease-causing virus or bacteria, but in a form that will not harm human body.

Herpes zoster, also known as shingles is caused by the reactivation of the varicella zoster virus (VZV), the same virus that causes chickenpox. Primary infection with VZV causes varicella. Once the illness resolves, the virus remains latent in the dorsal root ganglia. VZV can reactive later in a person’s life and cause a painful, maculopapular rash called herpes zoster. Postherpetic neuralgia (PHN) is the most common complication of herpes zoster. PHN is pain that persists in the area where the rash once was for more than 90 days after rash onset. PHN can last for weeks or months, and occasionally, for years. Two vaccines, zoster vaccine live (ZVL, Zostavax by Merck & Co., Inc) and recombinant zoster vaccine (RZV, Shingrix by GlaxoSmithKline plc), are common vaccines used.

Rising prevalence & incidences of shingles is anticipated to ensure a strong demand for shingles vaccination products worldwide. For instance, incidences of shingles have significantly risen in the US, with incidence rate among individuals belonging to the age group of 50-59 years, climbing from ~4.1 in 1998 to approximately 7.9 per 1000 people in 2016. Moreover, rising geriatric population has been one of the pivotal factors in contributing to the growth of the global shingles market. However, high costs associated with development, storage of vaccines is likely to restrain the market to a certain extent.

Shingles Vaccine Market By Product & By Patient Type

The global shingles market has primarily been segmented into two broad categories, viz. By Product and By Patient Type. The segment of product is further classified into Shingrix, Zostavax and Other Products (If Any). On the basis of product sales, the market for shingrix outnumbered that of Zostavax, owing to better efficiency and stronger protection against herpes zoster and PHN. Wheres, the segment of patient type is bifurcated into pediatric patients & adult patients.

Shingles Vaccine Market By Region

The global shingles market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). In 2018, North America accounted for the largest share in the global shingles vaccines, owing to availability of efficient healthcare insurance & reimbursement systems, better awareness, and favorable government regulations among others.

Shingles Vaccine Market Prominent Players

The global shingles market is majorly governed by GlaxoSmithKline plc., and Merck & Co., Inc.. and other players

Table of Contents

  1. INTRODUCTION
    1. Market Definition
    2. Market Classification
    3. Geographic Scope
    4. Years Considered for the Study: Historical Years – 2016 & 2017; Base Year – 2018; Forecast Years – 2019 to 2030
    5. Currency Used
  2. RESEARCH METHODOLOGY
    1. Research Framework
    2. Data Collection Technique
    3. Data Sources
      1.  Secondary Sources
      2.  Primary Sources
    4. Market Estimation Methodology
      1.  Bottom Up Approach
      2.  Top Down Approach
    5. Data Validation and Triangulation
      1.  Market Forecast Model
      2.  Limitations/Assumptions of the Study
  3. ABSTRACT OF THE STUDY
  4. MARKET DYNAMICS ASSESSMENT
    1. Overview
    2. Drivers
    3. Barriers/Challenges
    4. Opportunities
  5. UNIQUE SELLING PROPOSITIONS (USPs)
    1. Pipeline Assessment
    2. Epidemiological Assessment
    3. Competitive Landscape Assessment
  6. GLOBAL SHINGLES VACCINE MARKET - ANALYSIS & FORECAST, BY PRODUCT
    1. Shingrix
    2. Zostavax
    3. Other Products (If Any)
  7. GLOBAL SHINGLES VACCINE MARKET - ANALYSIS & FORECAST, BY PATIENT TYPE
    1. Pediatric Patients
    2. Adult Patients
  8. GLOBAL SHINGLES VACCINE- ANALYSIS & FORECAST, BY REGION
    1.   North America shingles vaccine Market
      1.  North America Shingles Vaccine Market, By Country
        1.  US
        2.  Canada
      2. North America Shingles Vaccine Market Analysis & Forecast, By Product
      3. North America Shingles Vaccine Market Analysis & Forecast, By Patient Type
    2. Europe Shingles Vaccine Market
      1. Europe Shingles Vaccine Market, By Country/Region
        1. Germany
        2. UK
        3. France
        4. Rest of Europe (ROE)
      2. Europe Shingles Vaccine Market Analysis & Forecast, By Product
      3. Europe Shingles Vaccine Market Analysis & Forecast, By Patient Type
    3. Asia Pacific Shingles Vaccine Market
      1. Asia Pacific Shingles Vaccine Market, By Country/Region
        1. China
        2. Japan
        3. India
        4. Rest of Asia Pacific (RoAPAC)
      2. Asia Pacific Shingles Vaccine  Market Analysis & Forecast, By Product
      3. Asia Pacific Shingles Vaccine Market Analysis & Forecast, By Patient Type
    4.   Rest of the World (ROW) Shingles Vaccine Market
      1. Rest of the World Shingles Vaccine Market, By Country/ Region
        1.  Latin America
        2.  Middle East & Africa
      2. Rest of the World Shingles Vaccine Market Analysis & Forecast, By Product
      3. Rest of the World Shingles Vaccine Market Analysis & Forecast, By Patient Type
  9. COMPANY PROFILES (Business Overview, Products Offered, Financial Performance*, Recent Developments)
    1.  GlaxoSmithKline plc.
    2.  Merck & Co., Inc.
    3. Other Players *Financial details might not be captured in case of privately-held companies or for companies that do not report this information in public domain